2019 American Society of Hematology Annual Meeting*

Download All
December 7-10, 2019; Orlando, Florida
CCO’s expert faculty review and share their expert perspectives on key findings in multiple myeloma presented at the 2019 ASH annual meeting.
Sagar Lonial, MD

Multiple Myeloma

Slidesets Phase I/II STOMP Trial: Selinexor, Pomalidomide, and Dexamethasone in R/R MM
Slidesets First Clinical Study of CC-93269, a BCMA 2+1 T-Cell Engager, in Relapsed/Refractory Myeloma
Slidesets Phase Ib/II CARTITUDE-1 Study of BCMA-Directed CAR T-Cell Therapy JNJ-4528 in Relapsed/Refractory Multiple Myeloma
Slidesets LEGEND-2 Long-term Follow-up: Phase I Trial of LCAR-B38M CAR T-Cell Therapy in R/R MM
Slidesets GRIFFIN Update: Phase II Study of Daratumumab + VRd vs VRd Alone for Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma
Slidesets CASSIOPET: CASSIOPEIA Companion Study Evaluating Prognostic Value of PET/CT in Newly Diagnosed, Transplant-Eligible Myeloma
Slidesets Phase III GEM-CLARIDEX: Clarithromycin Plus Rd vs Rd Alone in Newly Diagnosed, Transplant-Ineligible Patients with Myeloma
Slidesets Phase II HOVON 143 Trial: Interim Analysis of Ixazomib/Daratumumab/Low-Dose Dex in Unfit, Frail Patients With Newly Diagnosed Multiple Myeloma
Slidesets Phase II GEM-CESAR: Carfilzomib/Lenalidomide/Dexamethasone as Curative Regimen for High-Risk Smoldering Myeloma
Slidesets ALCYONE 3-Yr Follow-up: Daratumumab Plus VMP vs VMP Alone in Newly Diagnosed, Transplantation-Ineligible Myeloma
Slidesets MASTER Trial: Response-Adapted Dara-KRd Sequential Therapy in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma
Slidesets Phase II Trial of Daratumumab Plus Ixazomib/Lenalidomide/Dose-Modified Dexamethasone in Newly Diagnosed MM
Slidesets Venetoclax/Daratumumab/Dexamethasone ± Bortezomib in Patients With R/R MM: Initial Analysis of a Phase I/II Trial
Slidesets Phase I/II Study of Venetoclax + Dexamethasone in Patients With t(11;14) R/R Multiple Myeloma
Slidesets Phase III CANDOR Trial of Carfilzomib, Dexamethasone ± Daratumumab in Relapsed/Refractory Multiple Myeloma

Did you see the latest clinical data in myeloma? In this commentary, Sagar Lonial, MD, discusses the key studies on myeloma that were recently presented at ASH 2019.

Sagar Lonial, MD Released: February 26, 2020
Provided by the Annenberg Center for Health Sciences at Eisenhower in partnership with Clinical Care Options.
ACHS Logo
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
Celgene Corporation
Dova Pharmaceuticals, Inc.
Karyopharm Therapeutics
Loxo Oncology, Inc. a wholly owned subsidiary of Eli Lilly and Company
Pharmacyclics LLC, an AbbVie Company
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue